ePro : electronic solutions for patient-reported data
著者
書誌事項
ePro : electronic solutions for patient-reported data
Gower, c2010
- hardback : alk. p
- hardback : alk. pape
- ebook
- ebook
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
- 巻冊次
-
hardback : alk. pape ISBN 9780566087714
内容説明
Patient self-reported data has become increasingly important in today's clinical trials. Trials in some disease indications rely upon patient recorded diary data as the primary endpoint to demonstrate drug efficacy - including, for example, indications such as insomnia, migraine and pain. In addition, improvements in quality of life measured using patient questionnaires can now be included as claims on drug labelling. Traditionally these data have been collected using paper questionnaires and diaries issued to subjects. Regulators and the industry have become increasingly aware of the limitations of recording patient reported outcomes data on paper including data quality and integrity issues. As a result there is a growing interest in collection of patient reported outcomes data using electronic means (ePRO). Solutions include handheld PDAs, Interactive Voice Response (IVR) systems, and other site-based hardware such as touchscreen PCs. Recently, there has been much open debate with the regulators around the use of ePRO in clinical drug submissions. US and European agencies have approved new drugs that have included ePRO data in the submission dossier, but there are many questions around the adoption of the technology that concern the community. These include: c How should instruments developed on paper be adapted for electronic use, and what degree of validation should be done between paper and electronic forms? c How can researchers ensure they are complying with regulatory requirements including the PRO guidance published by FDA in 2009 when using ePRO solutions? c Can fewer patients be exposed in a clinical trial as a result of improved data quality obtained using electronic diaries? c What type of solution should be used for certain patient populations and protocols, and how can ePRO solutions be designed optimally to increase patient acceptability and compliance? Bill Byrom and Brian Tiplady's ePro addresses all these issues, reviews the new FDA guidance, and provides a very contemporary view on this important subject.
目次
- Introduction
- 1: Recall Bias: Understanding and Reducing Bias in PRO Data Collection
- 2: Cognitive Interviewing: The use of Cognitive Interviews to Evaluate ePRO Instruments
- 3: Data Quality and Power in Clinical Trials: A Comparison of ePRO and Paper in a Randomized Trial
- 4: Regulation and Compliance: Scientific and Technical Regulatory Issues Associated with Electronic Capture of Patient-reported Outcome Data
- 5: Selection of a Suitable ePRO Solution: Benefit, Cost and Risk
- 6: Patient Compliance in an ePRO Environment: Methods for Consistent Compliance Management, Measurement and Reporting
- 7: Computerised Clinical Assessments: Derived Complex Clinical Endpoints from Patient Self-report Data
- 8: Diary Design Considerations: Interface Issues and Patient Acceptability
- 9: Equivalence Testing: Validation and Supporting Evidence When Using Modified PRO Instruments
- 10: ePRO Applications and Personal Mobile Phone Use: Compliance Documentation and Patient Support
- 11: Future Developments and Applications: Emerging Technologies and New Approaches to Patients
- 巻冊次
-
ebook ISBN 9781409412427
内容説明
Patient self-reported data has become increasingly important in today's clinical trials. Trials in some disease indications rely upon patient recorded diary data as the primary endpoint to demonstrate drug efficacy - including, for example, indications such as insomnia, migraine and pain. In addition, improvements in quality of life measured using patient questionnaires can now be included as claims on drug labelling. Traditionally these data have been collected using paper questionnaires and diaries issued to subjects. Regulators and the industry have become increasingly aware of the limitations of recording patient reported outcomes data on paper including data quality and integrity issues. As a result there is a growing interest in collection of patient reported outcomes data using electronic means (ePRO). Solutions include handheld PDAs, Interactive Voice Response (IVR) systems, and other site-based hardware such as touchscreen PCs.
Recently, there has been much open debate with the regulators around the use of ePRO in clinical drug submissions. US and European agencies have approved new drugs that have included ePRO data in the submission dossier, but there are many questions around the adoption of the technology that concern the community. These include:
* How should instruments developed on paper be adapted for electronic use, and what degree of validation should be done between paper and electronic forms?
* How can researchers ensure they are complying with regulatory requirements including the PRO guidance published by FDA in 2009 when using ePRO solutions?
* Can fewer patients be exposed in a clinical trial as a result of improved data quality obtained using electronic diaries?
* What type of solution should be used for certain patient populations and protocols, and how can ePRO solutions be designed optimally to increase patient acceptability and compliance?
Bill Byrom and Brian Tiplady's ePro addresses all these issues, reviews the new FDA guidance, and provides a very contemporary view on this important subject.
目次
- Contents: Foreword, Stephen A. Raymond
- Introduction, Bill Byrom and Brian Tiplady
- Recall bias: understanding and reducing bias in PRO data collection, Alan L. Shields, Saul Shiffman and Arthur Stone
- Cognitive interviewing: the use of cognitive interviews to evaluate ePRO instruments, Paul C. Beatty
- Data quality and power in clinical trials: a comparison of ePRO and paper in a randomized trial, Allen L. Ganser, Stephen A. Raymond and Jay D. Pearson
- Regulation and compliance: scientific and technical regulatory issues associated with electronic capture of patient-reported outcome data, Sonya Eremenco and Dennis A. Revicki
- Selection of a suitable ePRO solution: benefit, cost and risk, Mikael Palmblad
- Patient compliance in an ePRO environment: methods for consistent compliance management, measurement and reporting, Alan L. Shields, Saul Shiffman and Arthur Stone
- Computerised clinical assessments: derived complex clinical endpoints from patient self-report data, Bill Byrom, Keith Wenzel and James Pierce
- Diary design considerations: interface issues and patient acceptability, Brian Tiplady
- Equivalence testing: validation and supporting evidence when using modified PRO instruments, Damian J. McEntegart
- ePRO applications and personal mobile phone use: compliance documentation and patient support, Breffni Martin
- Future developments and applications: emerging technologies and new approaches to patients, Brian Tiplady and Bill Byrom
- Index.
「Nielsen BookData」 より